Key Points {#FPar1}
==========

Specific treatments with undisputable safety and efficacy are still required for controlling viral replication, inflammation, and thrombotic risk during COVID-19.Acetylsalicylic acid has anti-inflammatory and antithrombotic effects, as well as some antiviral activity against DNA and RNA viruses.Whether acetylsalicylic acid might be a safe and reasonable therapeutic candidate to be tested in clinical trials involving adults with COVID-19 deserves further attention.

Introduction {#Sec1}
============

The recent pandemic of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) disease, termed COVID-19, has affected more than 10 million people and caused over 500,000 deaths worldwide (4 July 2020) \[[@CR1]\]. In patients with COVID-19, the infectious virus has been documented in the respiratory tract, where active viral replication and diffuse alveolar damage occur \[[@CR2], [@CR3]\]. Fever, respiratory symptoms and myalgia are the most frequent clinical features of COVID-19 \[[@CR4]\]. Importantly, lung and systemic inflammation are responsible for much of COVID-19′s severity \[[@CR5]\], which may ultimately cause severe respiratory failure, multi-organ dysfunction, and death \[[@CR6]\].

Thrombotic complications frequently occur in patients with COVID-19 \[[@CR7], [@CR8]\]. In this regard, thrombocytopenia, elevated fibrin degradation products, prothrombin time (PT), and activated partial thromboplastin time (aPTT) prolongation, venous thromboembolism and disseminated intravascular coagulation (DIC) have been reported in COVID-19 patients \[[@CR7]--[@CR9]\]. Importantly, a hypercoagulable state during viral infections can result in an increased risk of thrombotic events \[[@CR10]\]. More specifically, viral infections are commonly accompanied by platelet activation and aggregation, resulting in platelet consumption and thrombocytopenia \[[@CR11]\]. Furthermore, over-expression of thromboxane synthase (TBXAS) and Toll-like receptor 9 (*TLR9*) genes, which are strictly implicated in platelet aggregation \[[@CR12], [@CR13]\], has been documented in vitro during SARS-CoV infection \[[@CR14]\]. Due to the similarities between the different coronavirus (CoV)-mediated diseases, these results might also suggest the presence of increased platelet activity and aggregability in patients with COVID-19. This conclusion is partially supported by the evidence of platelet activation in patients with community-acquired pneumonia \[[@CR15]\].

Based on these premises, a detrimental interaction between SARS-CoV-2 replication into the respiratory tract, alveolar epithelium injury, lung and systemic inflammation, and platelet hyper-aggregability should be suspected and concomitantly managed in the most severe forms of COVID-19.

Acetylsalicylic acid (ASA), marketed in 1899 under the registered trademark of Aspirin, has anti-inflammatory, analgesic, antipyretic, and antithrombotic effects \[[@CR16]\]. These effects are obtained because ASA inhibits prostaglandin (PG) and thromboxane synthesis by irreversible inactivation of both cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2). Additional mechanisms of ASA-induced effects include, among the others, modulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF‐κB) pathway, down-regulation of inducible nitric oxide synthase (iNOS), oxidative phosphorylation uncoupling, and increased permeability in mitochondria \[[@CR17]\]. Along with its well-established role in reducing inflammation \[[@CR16]\] and platelet aggregation \[[@CR18]\], antiviral effects have also been proposed for ASA both against DNA and RNA viruses \[[@CR19]\]. Among the latter effects, [d]{.smallcaps},[l]{.smallcaps}-lysine acetylsalicylate (i.e., a lysine-salt formulation of ASA) reduced RNA synthesis and replication of the human CoV-229E and Middle East Respiratory Syndrome (MERS)-CoV titer in cultured infected cells \[[@CR20]\].

The aim of this review was to critically appraise current evidence on the potential benefits and risks of ASA, putting them in the context of the adult-restricted COVID-19 population.

Clinical Implications for SARS-CoV-2 Infection {#Sec2}
==============================================

There is compelling evidence suggesting that SARS-CoV-2 infection may be asymptomatic, pauci-symptomatic, or symptomatic \[[@CR21]\]. Although COVID-19 is generally a mild disease in children and infants, in some cases it may manifest in younger age groups as a multisystem inflammatory syndrome with Kawasaki's disease-like features (e.g., fever, mucocutaneous manifestations, cervical lymphadenopathy, conjunctival injection, cardiac involvement) or even multiorgan failure \[[@CR22]\]. In adulthood, the clinical spectrum of symptomatic SARS-CoV-2 infection is extremely heterogeneous, ranging from mild to severe and potentially life-threatening manifestations \[[@CR21]\]. The most common initial symptoms, including fever, dry cough, myalgia, or fatigue, are generally mild and non-specific \[[@CR21],[@CR23]\]. Less commonly, COVID-19 clinical onset is characterized by nausea, vomiting, diarrhea, abdominal pain, and anosmia with or without dysgeusia \[[@CR24], [@CR25]\]. A delayed progression to dyspnea with respiratory failure requiring hospital admission has been reported to occur in more than half of cases \[[@CR21], [@CR26]\]. According to different reports, hypertension, cardiovascular diseases, and diabetes mellitus are the three most prevalent underlying co-morbidities among COVID-19 patients undergoing hospitalization \[[@CR27]\]. Upon hospitalization, intensive care unit (ICU) admission may be required in about 20% of cases due to either acute respiratory distress syndrome (ARDS) or other severe complications, including DIC and other thrombotic disorders \[[@CR23]\]. Although early reports have described ARDS and multi-organ failure as the main in-hospital complications of COVID-19, more recent studies have shown that venous thromboembolism and arterial thrombosis have a high incidence rate and a detrimental impact on prognosis of hospitalized COVID-19 patients \[[@CR7], [@CR28]\]. In addition, evidence of myocardial injury, likely due to a combination of a direct virus-mediated and an indirect immune-mediated injury of cardiomyocytes, has been frequently found in patients with COVID-19 \[[@CR29], [@CR30]\]. In a Chinese cohort of 416 hospitalized patients with COVID-19, individuals with myocardial injury were more likely to necessitate ventilation and die because of COVID-19 complications \[[@CR31]\]. Also, in a Chinese case series of 72,314 COVID-19 patients, the overall case fatality rate was 2.3%, but it reached 6%, 7.3%, and 10.5% in patients with hypertension, diabetes, or underlying cardiovascular disease \[[@CR32]\]. Moreover, mortality exceeded 50% in a retrospective case series of 187 COVID-19 patients with myocardial injury \[[@CR33]\].

Clinical and laboratory features of hospitalized COVID-19 patients are predictive of COVID-19 progression towards its most severe clinical manifestations and fatal outcome \[[@CR34]--[@CR38]\]. These features include: older age, underlying co-morbidities, higher Sequential Organ Failure Assessment (SOFA) scores (indicative of organ dysfunction), abnormal hemostasis parameters (i.e., increased levels of D-dimer and fibrin degradation products, and decreased platelet counts) and increased biomarkers of cardiac injury and dysfunction (i.e., N-terminal pro-brain natriuretic peptide and troponin) \[[@CR34]--[@CR38]\]. Thus, in a retrospective case series of 187 COVID-19 patients, troponin T elevation was significantly associated with a greater probability of developing ARDS, arrythmias, and other complications as compared with troponin T within the normal range \[[@CR33]\].

The search of possible therapeutic strategies against SARS-CoV-2 is rapidly proceeding. To date, a number of potential target therapies have been proposed, including angiotensin-converting enzyme 2 (ACE2) inhibitors \[[@CR39]\]. Indeed, ACE2 is a crucial molecule in SARS-CoV-2 infection as viral particle entry into host cell is mediated by S protein interaction with ACE2 \[[@CR39]\]. However, given the current lack of approved specific therapies, COVID-19 treatment is currently based on supportive care, including symptomatic therapies for mild clinical manifestations and respiratory support \[[@CR40]\]. Several drugs approved for other indications as well as multiple investigational agents and potential therapies may provide new opportunities for treating patients infected with SARS-CoV-2. Therapeutic alternatives include specific (remdesivir seems the most promising compound) and non-specific antiviral agents, immune-modulatory agents, other anti-infective agents repurposed to treat COVID-19, and drugs acting on host cell receptors \[[@CR39]--[@CR42]\]. Future clinical studies are needed to highlight the possible pharmacological interactions of some investigational drugs used in the therapy of COVID-19-positive cancer patients with antineoplastic drugs \[[@CR43]\]. Moreover, the search for potential vaccines for COVID-19 is also rapidly progressing.

Coronavirus Infections and Thrombosis {#Sec3}
=====================================

An increased thrombotic risk has been observed in both SARS-CoV-1 and MERS-CoV, as confirmed in in vitro, experimental, and clinical studies. Over-expression of a significant number of genes involved in the upregulation of the coagulation cascade (e.g., fibrinogen, factors II, III, VII, X, XI, XII, serine proteinase inhibitors \[SERPINs\]) \[[@CR14], [@CR44]\] and platelet aggregation (e.g., *TBXAS, TLR9*) \[[@CR14]\] has been decribed in SARS-CoV-1-infected peripheral blood mononuclear cells and human hepatoma cells. Also, an excess of micro-vascular thrombi in the lung tissue of MERS-CoV-infected mice transgenic for human dipeptidyl peptidase 4 (DPP4) has been observed \[[@CR45]\]. Along with these changes, alterations of laboratory markers of increased thrombotic risk have been described in patients with SARS-CoV-1 and MERS-CoV. In this regard, thrombocytopenia, increased D-dimer, and prolonged PT and aPTT have been sparsely reported in SARS-CoV-1 and MERS-CoV infections \[[@CR8]\]. Overall, based on some case reports, the above reported hematologic manifestations of both SARS-CoV-1 and MERS-CoV infections translated into an increased risk of vein and arterial thrombosis and DIC \[[@CR46], [@CR47]\].

Laboratory findings in patients with SARS-CoV-2 infection are not dissimilar from those in SARS-CoV-1 and MERS-CoV infections, with relevant changes in blood coagulation parameters indicating an increased thrombotic risk \[[@CR9], [@CR48], [@CR49]\] (Fig. [1](#Fig1){ref-type="fig"}). Importantly, thrombocytopenia and elevation of plasma D-dimer levels have been found to be much more evident in patients with the most severe forms of COVID-19 \[[@CR4]\]. In addition, poor prognosis was observed among COVID-19 patients with higher D-dimer and prolonged PT \[[@CR50]\]. From a clinical perspective, increased prevalence of DIC \[[@CR51]\] and other vein and arterial thrombotic (e.g., small pulmonary arterioles) complications have been recorded in COVID-19 patients, with the highest prevalence among critically ill patients \[[@CR7], [@CR52], [@CR53]\]. In addition, the presence of antiphospholipid antibodies (e.g., anticardiolipin IgA, anti-β2-glycoprotein I IgA and IgG) \[[@CR54]\], which may contribute to an increased risk of both venous and arterial thrombosis, has been described in the serum of COVID-19 patients \[[@CR55], [@CR56]\]. Noteworthy, evidence of cardiac injury has been observed in a retrospective case series of 187 patients with COVID-19 \[[@CR33]\], the latter being a significant negative prognostic factor in this population \[[@CR31]\]. Direct viral myocardial injury, systemic overactivation of the inflammation cascade, as well as virus-induced atherosclerotic plaque destabilization and micro- and macro-vascular thrombosis have been proposed as possible mechanisms leading to cardiovascular manifestations of COVID-19 \[[@CR57]\]. In addition, several viral infections may start a hyper-inflammatory cytokine response, leading to platelet aggregation and micro- and macrovascular thrombosis (i.e., a condition called thrombo-inflammation) \[[@CR58]\]. Hence, drugs aimed at controlling all these important sequelae of COVID-19, including accelerated thrombo-inflammation, are eagerly anticipated. In this regard, and more specifically in the context of COVID-19, the role of ASA is unknown and results from ongoing clinical studies are awaited (Table [1](#Tab1){ref-type="table"}). Some conflicting evidence of an anti-inflammatory effect of heparin has been proposed \[[@CR59]\]. Currently, the association between the use of low molecular-weight heparin and short-term survival has also been examined in a retrospective analysis of 449 patients with severe COVID-19 \[[@CR60]\]. This study showed some evidence of protection from heparin use against 28-day COVID-19 mortality among severe COVID-19 patients (i.e., with either high sepsis-induced coagulopathy score or plasma D-dimer levels) \[[@CR60]\]. It is important to emphasize the extreme importance of risk stratification for venous thromboemolism in order to ensure the most appropriate protection from increased thrombotic risk in this specific population \[[@CR61]\].Fig. 1Proposed mechanisms for the increased thrombotic risk related to SARS-CoV-2 infection. *SARS-CoV-2* Severe Acute Respiratory Syndrome-Coronavirus-2Table 1Clinical studies investigating the effects of ASA in COVID-19 according to clinicaltrials.govStudy typeStudy identifierNumber of participantASA treatment (dose and duration)Primary outcome(s)Study phaseStatusInterventionalNCT04365309128ASA 100 mg dailyClinical recovery timeThe time of SARS-CoV-2 overcastingPhase 2Phase 3Enrolling by invitationInterventionalNCT043638401080ASA 81 mg daily for 14 daysHospitalizationPhase 2Not yet recruitingInterventionalNCT04410328132ASA 25 mg two times daily for 2 weeksChange in composite COVID ordinal scale at day 15Phase 3Not yet recruitingInterventionalNCT0434300110,000ASA 150 mg daily until death, discharge or 28 days after randomisation, whichever occurs firstDeathPhase 3Not yet recruitingInterventionalNCT043244634000ASA 75--100 mg once daily for 28 daysOutpatient trial: composite of hospitalization or deathInpatient trial: invasive mechanical ventilation or deathPhase 3RecruitingInterventionalNCT043683775ASA 250 mg IV before starting tirofiban followed by 75 mg daily for 30 daysChange in P/F ratioPaO~2~ differenceA-a O~2~ differencePhase 2CompletedInterventionalNCT043334073170ASA 75 mg dailyAll-cause mortality at 30 days after admissionNot applicableRecruitingObservationalNCT043901261200ASA any dose% adherence to each pharmacological classNumber of occurrence of medical events at 1 yearNot applicableActive not recruiting

Acetylsalicylic Acid as an Anti-Inflammatory Drug {#Sec4}
=================================================

ASA exerts its anti-inflammatory effects mostly as a non-selective inhibitor of cyclo-oxygenase (COX-1 and COX-2) enzymes, which are involved in the production of important mediators, including PGs and thromboxane A2 (TXA2), collectively called prostanoids \[[@CR16], [@CR18]\]. The enzyme COX-1 is constitutively expressed in several tissues and regulates basal levels of PGs, involved in the control of platelet activation and in protection of the gastrointestinal tract \[[@CR62]\]. In contrast to COX-1, COX-2 is inducible by inflammatory stimuli, hormones, and growth factors, also representing an important source of prostanoid formation during infections, injuries, and cancer \[[@CR63]\].

Through acetylation of specific serine residues in the COX-1 (e.g., Ser 530) or COX-2 (e.g., Ser 516) isoenzymes, ASA permanently blocks prostanoid biosynthesis, particularly the prostanoid precursors PGG2 and PGH2, blunting a variety of pro-inflammatory responses \[[@CR64]\]. Importantly, acetylation reactions induced by ASA lead to irreversible COX inhibition,thus, new COXs must be synthesized before more prostanoids can be produced \[[@CR64]\]. Additionally, proteomic studies have reported that ASA can increase acetylation of histone proteins, thus resulting in the regulation of gene expression \[[@CR65]\]. Better understanding of the ASA-induced acetylome might provide a novel interpretation of the anti-inflammatory effects of ASA and possibly of the additional functions ascribed to this drug, such as antiviral and antiplatelet effects. Although acetylation of COX enzymes is believed to be the primary mechanism for the anti-inflammatory effects of ASA, additional actions have been described for explaining the ability of ASA to suppress inflammation, including: (1) suppression of the prototypical proinflammatory signaling pathway NF-κB \[[@CR66]\], (2) induction of heme oxygenase (HO) expression \[[@CR67]\], and (3) acetylation of iNOS, resulting in the release of nitric oxide \[[@CR68]\].

The potent anti-inflammatory effects of ASA have been exploited in clinical practice. At intermediate-to-high doses (650 mg to 4 g/day), ASA is able to irreversibly inhibit both COX-1 and COX-2, and at these doses ASA has been used for treating severe inflammatory disorders (e.g., rheumatic fever, Kawasaki disease, adult-onset Still's disease, and recurrent pericarditis) \[[@CR69]--[@CR74]\]. Significant improvement of some inflammation-related symptoms (e.g., fever, joint symptoms) and reductions of plasma levels of inflammation markers (e.g., white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) have been obtained with the use of intermediate-to-high doses of ASA in all the aforementioned conditions \[[@CR69]--[@CR74]\]. In addition, a single high dose of ASA has improved symptoms related to both the common cold and flu, including fever, myalgias, headache, and sore throat \[[@CR75], [@CR76]\]. Importantly, overactivation of COXs \[[@CR77]\], NF-κB, and systemic cytokine responses \[[@CR5], [@CR20]\], along with occurrence of inflammation-related symptoms \[[@CR4]\], are all typical hallmarks of viral infections,most of these conditions are also present in the course of COVID-19 \[[@CR4][@CR5], [@CR20]\].

Acetylsalicylic Acid as an Anti-Thrombotic Drug {#Sec5}
===============================================

Low doses of ASA (e.g., 75--100 mg/day) are sufficient to irreversibly acetylate Ser 530 of COX-1, thus preferentially inhibiting platelet generation of TXA2, a potent vasoconstrictor and stimulator of platelet reactivity \[[@CR78]\]. TXA2 inhibition by ASA results in a significant antithrombotic effect \[[@CR79]\]. However, it is important to emphasize that the production of additional prostanoids (e.g., PGI2) by cells other than platelets (e.g., endothelial cells, arterial smooth muscle cells) can be reduced by ASA via COX-1 and COX-2 inhibition, depending on individual susceptibility, COX metabolism in different cell types, ASA doses, and additional factors \[[@CR79]\]. In this respect, higher doses of ASA can reduce production of PGI2, a prostanoid opposing to the function of TXA2, thus potentially being less efficacious in terms of antithrombotic effects as compared to lower doses of ASA \[[@CR80], [@CR81]\]. However, with respect to PGI2, there is solid evidence that when ASA is used at lower doses, TXA2 inhibition greatly overcomes PGI2 inhibition, resulting in an overall antithrombotic effect \[[@CR81], [@CR82]\].

In order to obtain a significant inhibition of platelet activity and aggregation, a high level of COX-1 inhibition is necessary \[[@CR82]\], this result can be obtained rapidly by using higher ASA doses (i.e., ≥ 300 mg daily), and in the long term by using lower doses (i.e., 75--100 mg daily) \[[@CR83]\]. The efficacy of low doses of ASA as an antiplatelet agent has been documented in several randomized controlled trials, with evidence of non-superiority for higher doses as compared to lower doses in terms of antithrombotic efficacy \[[@CR84]\]. Based on this evidence and on the results of additional randomized clinical trials, low doses of ASA are currently used for inhibiting platelet aggregation and preventing ischemic arterial events (e.g., myocardial infarction, stroke) in patients at higher thrombotic risk \[[@CR85]\]. In addition, due to its antiplatelet effects, ASA at low doses is currently recommended for preventing thrombotic manifestations in pregnant women with antiphospholipid antibody syndrome, mechanical heart valves, or at intermediate-to-high risk of pre-eclampsia \[[@CR86], [@CR87]\].

In addition to its ability to prevent arterial thrombo-embolic events, there is some evidence that ASA may also reduce venous thromboembolism. In this regard, the pooled results of the Warfarin and Aspirin (WARFASA) and the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trials showed that in patients with a first unprovoked venous thromboembolism, after warfarin was discontinued, ASA reduced the risk of thrombotic event recurrence by 32% \[[@CR88]\]. Mechanisms alternative to COX inhibition have been proposed to explain ASA-mediated antithrombotic effects, including the ability of ASA to cause acetylation of proteins involved in the coagulation cascade (e.g., fibrinogen), thus promoting fibrinolysis \[[@CR89]\]. A recent meta-analysis of 13 randomized clinical trials showed that the efficacy of ASA for venous thromboembolism prophylaxis in patients undergoing total hip replacement or total knee replacement was not different from that of other anticoagulants \[[@CR90]\]. Despite these intriguing results, the central role of the non-vitamin K antagonist oral anticoagulants in the prevention of recurrent venous thromboembolism must be emphasized \[[@CR91], [@CR92]\].

Irrespective of the relative superiority of different drug regimens in preventing venous thromboembolism, a large body of evidence supports an overall antithrombotic action of ASA that might be exploited in those conditions (e.g., infections) in which additional effects of ASA (e.g., anti-inflammatory, antiviral) may be required. In this regard, there is some preliminary experimental and clinical evidence suggesting that ASA may serve as a potential preventive/therapeutic strategy against infection-induced coagulopathy and DIC. Indeed, it has been demonstrated that ASA can inhibit intravascular coagulation during *Staphylococcus aureus-*induced sepsis in mice by reducing platelet activation and intravascular thrombin activity \[[@CR93]\]. In addition, in a retrospective study including 390 septic shock patients from intensive care units (ICUs) antiplatelet therapy prior to hospital admission was associated with a decreased risk of overt DIC \[[@CR94]\].

Acetylsalicylic Acid as an Antiviral Drug {#Sec6}
=========================================

The antiviral effects of salicylic acid, the principal metabolite of ASA, have already been described in plants. Salicylic acid, either produced by plants or applied to them, can induce resistance to viral infections; through this and other immune-modulating functions, salicylic acid is currently considered a plant protector from viruses and other kind of biotic and abiotic stresses \[[@CR95]\].

In humans, the antiviral action of ASA has been extensively documented against both DNA and RNA viruses (Fig. [2](#Fig2){ref-type="fig"}). ASA reduced cytomegalovirus-induced reactive oxygen species production and NF‐κB activation, thus resulting in the inhibition of cytomegalovirus replication in smooth muscle cells \[[@CR96]\]. Also, high doses of ASA have been shown to be able to reduce varicella-zoster virus replication in a partially reversible manner \[[@CR97], [@CR98]\], with ASA concentration and duration of exposure of infected cells to ASA influencing reversibility \[[@CR97]\]. In the setting of RNA viruses, ASA has been demonstrated to stimulate the over-expression of several proteins (e.g., ubiquitin-protein ligase E6A, adenylosuccinate lyase, and nibrin) that are responsible for the inhibition of hepatitis C virus (HCV) replication \[[@CR99]\]. The inhibitory activity of ASA on HCV has been found to be mediated in part by COX-2 inhibition \[[@CR100]\]. ASA has also been shown to enhance the proteasomal degradation of claudin-1, which serves as a HCV receptor, thereby reducing the entry of virus particles \[[@CR101]\]. There is also evidence suggesting that ASA can down-regulate the promoter activity of iNOS in HCV-infected cells by reducing its affinity to CCAAT/enhancer-binding protein-beta (C/EBP-β), thereby inhibiting iNOS expression and HCV-RNA replication \[[@CR102]\]. Another study showed that ASA could reduce the pathogenic effects of HCV through the down-regulation of cellular oxidative stress and the enhancement of the expression and activity of Cu/Zn superoxide dismutase (SOD1) in infected cells \[[@CR103]\]. Additionally, ASA showed a significant and dose-dependent antiviral activity against several other RNA viruses, including influenza A H1N1 virus, human rhinoviruses, and coxsackie virus subtype A9, this effect was observed with non-cytotoxic doses of ASA \[[@CR19]\]. It is noteworthy that the beneficial effects of ASA against influenza virus infection have been in part attributed to ASA-mediated inhibition of PGE2 activity in macrophages and subsequent upregulation of interferon type I (IFN-1) production, leading to restricted viral replication and promoting T-cell-mediated immune response \[[@CR104]\].Fig. 2Hypothetical mechanisms explaining the antiviral effects of ASA. In the grey circle are included: three main antiviral pathways modulated by ASA, including COX-2, NF-kB, and HO-1, and the proposed mechanisms mediating the antiviral effects of ASA. The external area includes the viruses whose replication is inhibithed by ASA: DNA viruses (CMV, V-Z) and RNA viruses (RNV, CXV, HCV, H1N1, CoV-229E, MERS-CoV). *ASA* acetylsalicylic acid, *CoV-229E* coronavirus-229E, *COX-2* cyclo-oxygenase-2, *CMV* cytomegalovirus, *CXV* coxackie virus, *HCV* hepatitis C virus, *HO-1* heme-oxygenase-1, *H1N1* influenza virus, *MERS-CoV* Middle East Respiratory Syndrome--Coronavirus; *NF-kB* nuclear factor kappa beta, *ROS* reactive oxygen species, *RNV* rhinovirus, *V-Z* varicella-zoster virus

Importantly, ASA-induced overactivation of HO-1 may result in the degradation of heme, which plays a role as a pro-inflammatory mediator \[[@CR67], [@CR105]\]. This anti-inflammatory mechanism of action of ASA is important in the light of two main findings: (1) the reduced lung inflammation and mortality in mice over-expressing HO-1 that are subsequently infected with influenza virus \[[@CR106]\], (2) the decreased HO-1 expression and/or activity due to human polymorphisms of the *HO-1* gene have been associated with poor outcomes in different states of overactivation of the inflammation cascade \[[@CR107]\]. Furthermore, non-toxic concentrations of [d]{.smallcaps},[l]{.smallcaps}-lysine acetylsalicylate, the water-soluble salt of ASA and lysine, reduced the titer, viral RNA synthesis, and protein accumulation, as well as the replication of human CoV-229E in vitro \[[@CR20]\]. In the same experimental conditions, [d]{.smallcaps},[l]{.smallcaps}-lysine acetylsalicylate reduced MERS-CoV titer in Huh7-infected cells \[[@CR20]\].

The above-mentioned antiviral effects of ASA were related in most cases to the inhibition of the virus-induced NF‐κB pathway \[[@CR20], [@CR108]\]. However, NF‐κB‐independent pathways have also been reported to be modulated by ASA during inhibition of viral activity \[[@CR109]\]. For instance, Liao et al*.* showed NF‐κB‐ and COX-independent antiviral effects of ASA against flavivirus infection and suggested that this inhibitory effect could be mediated by p38 MAP kinase activation \[[@CR109]\].

The issue regarding the ability of ASA to exert an antiviral activity partly by inhibiting NF‐κB is of extreme importance in the light of the dual and intricate role of NF‐κB as a regulator of the antiviral response. On the one hand, viruses inhibit the NF‐κB pathway by encoding several NF‐κB inhibitors and interfering with receptors and adaptor proteins related to the NF‐κB pathway \[[@CR110]\], these actions are believed to represent just one of the several mechanisms adopted by different viruses to escape host immunity \[[@CR110]\]. On the other hand, pro-viral effects of NF‐κB activation have been described as well. Thus, for instance, a negative inhibitor of NF-κB kinase β (IKKβ) mutation may result in impaired NF‐κB signaling pathway and reduced viral replication \[[@CR111]\]. Many additional examples of the pro-viral effects resulting from NF‐κB activation have been also reported \[[@CR112]\]. For instance, human CoV-229E-mediated activation of NF-κB has been demonstrated to be crucial for viral propagation in the early phase of infection \[[@CR20]\].

All the above-reported effects of ASA on viral infection and propagation, and the related proposed mechanisms to explain such an effect, were derived from in vitro and experimental research. Whether similar effects might be extended to adult humans is a matter of discussion. In this regard, the use of ASA at over-the-counter doses in adult patients with flu and the common cold is relatively common and effective in relieving symptoms of acute upper respiratory tract viral infections like fever, myalgias, headache, and sore throat \[[@CR75], [@CR76]\]. However, it is likely that the anti-inflammatory activity of ASA, instead of antiviral activity, may be responsible for the rapid symptom relief following a single dose of ASA. Clinical studies are necessary to test whether a course of ASA therapy may improve symptoms and also exert a significant antiviral effect.

Clinical Applications of Acetylsalicylic Acid in Infectious Diseases {#Sec7}
====================================================================

The multifaceted pharmacological effects of ASA, involving the modulation of immune-inflammation pathways, thrombosis, and viral infectivity, have been exploited as potential clinical applications in different infectious diseases.

During severe sepsis and viral infections, overactivation of the inflammation cascade, platelet hyper-reactivity, platelet-leukocyte interaction, and other detrimental molecular events occur; these phenomena may lead to systemic and pulmonary microvascular thrombosis and intravascular coagulation, which in turn increase the risk of ARDS, multi-organ failure, and death \[[@CR113]\]. Also, ischemic cardiovascular events may complicate the early and late course of severe infections \[[@CR114]\]. Thus, ASA, as an effective drug for the prevention of ischemic cardiovascular events \[[@CR85]\] might be particularly useful in patients with infectious diseases.

A meta-analysis of three observational studies in mixed critically ill patients found a beneficial effect of ASA on the incidence of ARDS (odds ratio (OR) 0.59, 95% confidence interval (CI) 0.36--0.98) \[[@CR115]\]. A number of clinical studies in patients affected by diseases of different degrees of clinical severity (e.g., critically ill, admitted to ICUs, with sepsis, severe sepsis, community-acquired pneumonia) showed that the use of ASA was associated with lower mortality \[[@CR116], [@CR117]\]. These beneficial effects of ASA have been confirmed by an individual patient data meta-analysis of published observational cohort data showing a reduced sepsis-related mortality in patients taking ASA prior to the onset of sepsis \[[@CR118]\]. A more recent meta-analysis of ten cohort studies enrolling 689,897 patients with sepsis revealed that ASA, administered either before or after sepsis, reduced ICU or hospital mortality \[[@CR119]\]. Altogether, these findings might support the clinical usefulness of ASA in improving overall survival in patients with sepsis and, more generally, in critically ill patients.

Modulation of thrombo-inflammation has been suggested as the mechanism underlying the beneficial effects of ASA during infections \[[@CR120]\]. However, additional clinical benefits of ASA in the setting of sepsis have been described. In a randomized, double-blind, placebo-controlled study ASA was able to partially reverse endotoxin tolerance in healthy subjects challenged intravenously with endotoxin \[[@CR121]\]. Also, in a randomized, double-blind, placebo-controlled study enrolling 30 healthy volunteers, endotoxin-induced platelet plug formation was attenuated by ASA, thus further supporting a possible antithrombotic action of ASA in septic patients \[[@CR122]\].

In the setting of infections from viral pathogens, ASA has also shown interesting results, albeit the level of evidence in this setting being less marked than in sepsis. In this regard, it has been found that persistent platelet activation intervenes in inflammatory, thrombotic, and virologic responses in human immunodeficiency virus (HIV) infection \[[@CR123]\]. Thus, results of a case--control study showing the ability of ASA to attenuate platelet aggregation, T-cell and monocyte activation, and enhance leukocyte responses to toll-like receptor stimulation in virologically suppressed HIV-infected subjects on antiretroviral therapy are particularly valuable \[[@CR124]\]. Importantly, the antiplatelet effects of ASA have also been observed in a randomized, placebo-controlled, crossover study enrolling 40 HIV-infected subjects treated with abacavir-related platelet hyper-reactivity \[[@CR125]\]. It must be reported that in a randomized controlled trial of 121 virologically suppressed subjects living with HIV, 12-week use of ASA did not affect markers of immune activation \[[@CR126]\]. Conversely, a significant reduction of plasma monocyte chemoattractant protein-1 levels and mucosal HIV target CCR5+ CD4+ cells has been obtained following 6-week ASA treatment in a randomized clinical trial enrolling 76 HIV seronegative women \[[@CR127]\]. Furthermore, in a phase 2 proof-of-concept study, aerosolized [d]{.smallcaps},[l]{.smallcaps}-lysine-acetylsalicylate glycine, which showed antiviral activity against human CoV-229E and MERS-CoV in vitro \[[@CR20]\], was also effective in reducing the time to symptom alleviation in hospitalized patients with influenza \[[@CR128]\]. Similarly, in a randomized, placebo-controlled study, ASA significantly reduced symptoms of upper respiratory tract infections of suspected viral origin (i.e., fever, headache, myalgias, general discomfort) compared with placebo \[[@CR75]\].

Altogether, these results in human infections, along with those obtained in the pre-clinical setting, may support the utility of ASA in mitigating the thrombo-inflammation-related complications associated with infections and possibly COVID-19.

Potential Side Effects of Acetylsalicylic Acid {#Sec8}
==============================================

Concern over the use of ASA are mostly related to side effects occurring in four main situations: (1) long-term course of therapy with intermediate-to-high doses in rheumatic-immune disorders; (2) long-term use of low doses for the prevention of ischemic cardiovascular diseases; (3) use of low doses for the prevention of thrombotic complications during pregnancy; (4) short-term use of high doses in children with a viral infection.

Irrespective of its effectiveness, intermediate-to-high doses of ASA have been used for the treatment of different rheumatic-immune disorders, including rheumatic fever, Kawasaki disease, adult-onset Still's disease, and recurrent pericarditis \[[@CR69]--[@CR73]\]. In some of these conditions, side effects of ASA, mainly gastrointestinal (e.g., nausea, epigastric pain or discomfort, and bleeding), were rare and generally related to the long-term use of high ASA doses \[[@CR129], [@CR130]\].

Long-term use of low doses of ASA are currently the mainstay of secondary prevention of ischemic cardiovascular diseases \[[@CR131]\]. The benefit-to-risk ratio of using low-dose ASA in this specific population is highly favorable when considering the number of ischemic events prevented \[[@CR130]\] and the potential risk of significant adverse events (i.e., gastrointestinal bleeding) \[[@CR132]\]. The relatively low risk of serious bleeding in younger individuals becomes significantly higher in older individuals (aged ≥ 75 years) \[[@CR133]\] and it has been shown to be greatly reduced by the concomitant use of proton-pump inhibitors or H~2~-receptor antagonists \[[@CR134]\].

The main safety concern related to the prophylactic use of low doses of ASA for the prevention of thrombotic complications during pregnancy is the potential bleeding risk. According to available evidence, the benefit-to-risk ratio of ASA use for this indication is unfavorable only in thrombocytopenic women and in the third trimester of pregnancy, when ASA could contribute to severe bleeding in women, and cesarean delivery may be urgently indicated in different maternal conditions \[[@CR86], [@CR87]\]. Therefore, a careful evaluation of gestational age and platelet count should be taken into account when starting ASA in pregnancy.

Short-term use of high doses of ASA in children with infections (e.g., mostly influenza A and B, varicella, but also other viral and bacterial infections) has been associated with the occurrence of a rare but life‐threatening complication called Reye's syndrome \[[@CR135], [@CR136]\]. This is characterized by the concomitant onset of an acute non-inflammatory encephalopathy and fatty liver failure \[[@CR135], [@CR136]\]. The incidence of Reye's syndrome fell from 0.6 to 0.1 cases per 100,000 in the UK following the warning against the use of ASA in children \[[@CR136]\]. Although it is typically observed in children, very rare cases of Reye's syndrome have been reported among adults \[[@CR137]\]. Rare cases of children with Reye's syndrome who did not have side effects when ASA rechallenge was attempted in adulthood have been described \[[@CR138]\].

Finally, the use of ASA for the treatment of either the common cold or flu symptoms in adults is generally safe and with side effects that are numerically comparable to those from other non-steroidal anti-inflammatory drugs (e.g., ibuprofen) or paracetamol \[[@CR139]\]. However, attention should be paid when considering the use of ASA in specific populations \[[@CR16]\].

Potential Role of Acetylsalicylic Acid in COVID-19 {#Sec9}
==================================================

The use of non-steroidal anti-inflammatory drugs (NSAIDs), including ASA, in COVID-19 patients has been a matter of intense debate. Indeed, based on some previous reports on acute respiratory infections, concerns have been raised regarding a possible increased risk of adverse events (e.g., multi-organ failure, ARDS, and death) with the use of NSAIDs in COVID-19 \[[@CR87], [@CR140]\]. Supporting this notion, experimental evidence suggests that these drugs may alter neutrophil function, thereby negatively influencing resolution of inflammation in acute respiratory infections \[[@CR141]\]. Nonetheless, major scientific societies and regulatory authorities worldwide have produced advisory documents to discourage either avoidance or discontinuation of NSAIDs in COVID-19, given the absence of a high level of evidence on their possible association with severe adverse outcomes in this specific setting \[[@CR142]--[@CR144]\].

Conversely, It should be considered that among NSAIDs, ASA has multifaceted pharmacological properties, which could exert potential benefits and provide a rationale for its use as supportive therapy in COVID-19 patients. First, it may be useful for the relief of aspecific symptoms of COVID-19, due to its analgesic and antipyretic effects \[[@CR16]\]. Second, it may exert anti-inflammatory, antithrombotic, and antiviral effects \[[@CR16], [@CR18],[@CR20], [@CR81], [@CR85], [@CR131]\], which altogether may be useful to inhibit the pathophysiological processes leading to the most severe clinical manifestations of COVID-19. Hence, ASA might reasonably be a therapeutic candidate to be tested in COVID-19. Timing of ASA initiation, dosing, duration of treatment, and subgroups of COVID-19 patients that can benefit most from the antiviral, anti-inflammatory, and antithrombotic actions of ASA need to be established (Table [1](#Tab1){ref-type="table"}). The clinical context of possible use of ASA should also be evaluated with caution in the light of the benefit-to-risk ratio. In this regard, side effects of and contraindications to ASA must always be kept in mind, with particular reference to bleeding risk (either in patients taking ASA for the prevention of cardiovascular events or in women taking ASA for the prevention of thrombotic complications in pregnancy) and Reye's syndrome onset in children. Hence, patients at increased risk of bleeding and children should be excluded from ASA treatment. However, the epidemiological observation that children are markedly less likely to develop COVID-19 and its outcomes deserves attention \[[@CR145]\]. Also, it should be considered that there is no current evidence suggesting that low doses of ASA in COVID-19 pregnant women or in COVID-19 patients at high/very high cardiovascular risk are associated with an increased risk of bleeding.

To our knowledge a number of observational and interventional studies are currently investigating the efficacy and safety of this drug at different doses in COVID-19 (Table [1](#Tab1){ref-type="table"}). Results from these studies will be crucial to either validate or refute the hypothesis that ASA could be a safe and potentially useful choice for adult patients with COVID-19.

Conclusions {#Sec10}
===========

COVID-19 has presented a serious challenge for the entire world, causing tremendous health, social, and economic consequences. From a pathophysiological perspective, much of the clinical consequences of SARS-CoV-2 infection are due to the elevated viral infectiveness and the ability of the virus to produce significant injury in the respiratory tract \[[@CR2]--[@CR6]\]. SARS-CoV-2 is also able to overactivate local and systemic inflammation cascades, and to promote a detrimental and progressive state of hyper-coagulability and platelet aggregability leading to micro- and macro-vascular thrombotic events \[[@CR7]--[@CR9]\]. This latter binomium of pathological events evoked by the viral infection configures the so-called state of thrombo-inflammation, an event that has been observed in other viral and non-viral infections \[[@CR58]\].

Currently, there is no specific pharmacological recommendation for the treatment of COVID-19, though antiviral, immune-modulatory, anti-inflammatory, and antithrombotic agents are currently used and other drugs are being tested in clinical trials \[[@CR39]--[@CR42]\]. Also, a vaccine against SARS-CoV-2 is not yet available. Hence, current treatment strategies need to be repurposed and targeted against the thrombo-inflammation cascade. In this regard, the long-lasting use of ASA as an anti-inflammatory and antithrombotic agent has been documented over decades \[[@CR16], [@CR18]\]. In addition to the anti-inflammatory and antiplatelet effects of ASA, much solid evidence from in vitro and experimental models supports the capacity of ASA to reduce replication, propagation, and infectivity of several RNA-enveloped viruses, including human CoV-229E and MERS-CoV \[[@CR20]\]. Also, ASA improved survival among patients with different types of infections, the latter conditions being characterized by overactivation of the inflammation cascade and enhanced platelet reactivity \[[@CR96]--[@CR101]\]. Altogether, these data, along with the recognized ability of ASA to mitigate several symptoms related to common viral infections, might support the notion to include ASA among the drugs deserving to be tested in patients with COVID-19. Overall, a critical appraisal of the clinical effects derived from testing ASA in adults with COVID-19 would add much to a still incomplete knowledge base and, hopefully, improve our ability to mitigate the disastrous clinical consequences of SARS-CoV-2 infection.
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